Literature DB >> 10696026

MR spectroscopy in gliomatosis cerebri.

M Bendszus1, M Warmuth-Metz, R Klein, R Burger, C Schichor, J C Tonn, L Solymosi.   

Abstract

BACKGROUND AND
PURPOSE: The diagnosis of gliomatosis cerebri with MR imaging is known to be difficult. We report on the value of MR spectroscopy in the diagnosis, grading, and biopsy planing in eight patients with histopathologically proved gliomatosis cerebri.
METHODS: Patients underwent MR imaging and MR spectroscopy (single-voxel point-resolved spectroscopy [PRESS] at 1500/135, and chemical-shift imaging [CSI] PRESS at 1500/135) before open (n = 4) or stereotactic (n = 4) biopsy. In six patients who underwent CSI, biopsy samples were taken from regions of maximally elevated levels of choline/N-acetylaspartate (Cho/NAA).
RESULTS: All patients showed elevated Cho/creatine (Cr) and Cho/NAA levels as well as varying degrees of decreased NAA/Cr ratios, which were most pronounced in the anaplastic lesions. In low-grade lesions, there was a maximum Cho/NAA ratio of 1.3, whereas in anaplastic tumors, the maximum Cho/NAA level was at least 2.5. Spectra in two patients with grade III lesions revealed a lactate peak; lactate and lipid signals were seen in two patients with grade IV lesions. Biopsy specimens from regions with maximally elevated levels of Cho/NAA showed dense infiltration of tumor cells.
CONCLUSION: MR spectroscopy might be used to classify gliomatosis cerebri as a stable or a progressive disease indicating its potential therapeutic relevance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10696026      PMCID: PMC7975356     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  41 in total

1.  Gadopentetate-dimeglumine-enhanced MR imaging of gliomatosis cerebri: appearance mimicking leptomeningeal tumor dissemination.

Authors:  D J Rippe; O B Boyko; G N Fuller; H S Friedman; W J Oakes; S C Schold
Journal:  AJNR Am J Neuroradiol       Date:  1990 Jul-Aug       Impact factor: 3.825

2.  Difficulties in the antemortem diagnosis of gliomatosis cerebri: report of a case with diffuse increase of gemistocyte-like cells, mimicking reactive gliosis.

Authors:  H Nishioka; H Ito; T Miki
Journal:  Br J Neurosurg       Date:  1996-02       Impact factor: 1.596

3.  MR and positron emission tomography with fludeoxyglucose F 18 in gliomatosis cerebri.

Authors:  M A Dexter; G D Parker; M Besser; J Ell; M J Fulham
Journal:  AJNR Am J Neuroradiol       Date:  1995-08       Impact factor: 3.825

4.  Proton magnetic resonance spectroscopy (1H-MRS) for the evaluation of treatment of brain tumours.

Authors:  K Houkin; K Kamada; Y Sawamura; Y Iwasaki; H Abe; T Kashiwaba
Journal:  Neuroradiology       Date:  1995-02       Impact factor: 2.804

5.  Chromosomes in gliomatosis cerebri.

Authors:  B K Hecht; C Turc-Carel; M Chatel; M Lonjon; J L Roche; J Gioanni; F Hecht; P Gaudray
Journal:  Genes Chromosomes Cancer       Date:  1995-10       Impact factor: 5.006

6.  Characterization of intracranial mass lesions with in vivo proton MR spectroscopy.

Authors:  H Poptani; R K Gupta; R Roy; R Pandey; V K Jain; D K Chhabra
Journal:  AJNR Am J Neuroradiol       Date:  1995-09       Impact factor: 3.825

7.  Magnetic resonance imaging determination of gliomatosis cerebri.

Authors:  M V Spagnoli; R I Grossman; R J Packer; D B Hackney; H I Goldberg; R A Zimmerman; L T Bilaniuk
Journal:  Neuroradiology       Date:  1987       Impact factor: 2.804

8.  Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors.

Authors:  H Bruhn; J Frahm; M L Gyngell; K D Merboldt; W Hänicke; R Sauter; C Hamburger
Journal:  Radiology       Date:  1989-08       Impact factor: 11.105

9.  Gliomatosis cerebri: clinical features, treatment, and prognosis.

Authors:  D G Kim; H J Yang; I A Park; J G Chi; H W Jung; D H Han; K S Choi; B K Cho
Journal:  Acta Neurochir (Wien)       Date:  1998       Impact factor: 2.216

10.  Computed tomography of gliomatosis cerebri.

Authors:  G K Geremia; R Wollman; R Foust
Journal:  J Comput Assist Tomogr       Date:  1988 Jul-Aug       Impact factor: 1.826

View more
  21 in total

1.  Gliomatosis cerebri has normal relative blood volume: really?! Who cares? Should you?

Authors:  Michael H Lev
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

2.  Dynamic contrast-enhanced T2*-weighted MR imaging of gliomatosis cerebri.

Authors:  Stanley Yang; Stephan Wetzel; M Law; D Zagzag; Soonmee Cha
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

3.  Incidence and survival of gliomatosis cerebri: a population-based cancer registration study.

Authors:  Marios K Georgakis; Dimitrios Spinos; Apostolos Pourtsidis; Amanda Psyrri; Ioannis G Panourias; Spyridon Sgouros; Eleni Th Petridou
Journal:  J Neurooncol       Date:  2018-02-20       Impact factor: 4.130

4.  Lack of choline elevation on proton magnetic resonance spectroscopy in grade I-III gliomas.

Authors:  Sanjeev Chawla; Seung-Cheol Lee; Suyash Mohan; Sumei Wang; MacLean Nasrallah; Arastoo Vossough; Jaroslaw Krejza; Elias R Melhem; S Ali Nabavizadeh
Journal:  Neuroradiol J       Date:  2019-05-03

5.  Histological and MR correlations in Gliomatosis cerebri.

Authors:  Paule Peretti-Viton; Hervé Brunel; Olivier Chinot; Clément Daniel; Maryline Barrié; Corinne Bouvier; Dominique Figarella-Branger; Stéphane Fuentes; Henry Dufour; François Grisoli
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

6.  MR spectroscopy in the evaluation of recurrent contrast-enhancing lesions in the posterior fossa after tumor treatment.

Authors:  P Weybright; P Maly; D Gomez-Hassan; C Blaesing; P C Sundgren
Journal:  Neuroradiology       Date:  2004-04-23       Impact factor: 2.804

7.  Presentation patterns and outcome of gliomatosis cerebri.

Authors:  Gustavo G Rajz; Dvora Nass; Elisa Talianski; Raphael Pfeffer; Roberto Spiegelmann; Zvi R Cohen
Journal:  Oncol Lett       Date:  2011-10-18       Impact factor: 2.967

8.  Gliomatosis cerebri: clinical characteristics, management, and outcomes.

Authors:  Selby Chen; Shota Tanaka; Caterina Giannini; Jonathan Morris; Elizabeth S Yan; Jan Buckner; Daniel H Lachance; Ian F Parney
Journal:  J Neurooncol       Date:  2013-01-23       Impact factor: 4.130

9.  Preoperative proton-MR spectroscopy of gliomas--correlation with quantitative nuclear morphology in surgical specimen.

Authors:  Reinhold Nafe; Sebastian Herminghaus; Peter Raab; Sabine Wagner; Ulrich Pilatus; Berthold Schneider; Wolfgang Schlote; Friedhelm Zanella; Heinrich Lanfermann
Journal:  J Neurooncol       Date:  2003-07       Impact factor: 4.130

10.  Proton MR spectroscopy of gliomatosis cerebri: case report of elevated myoinositol with normal choline levels.

Authors:  Efrat Saraf-Lavi; Brian C Bowen; Pradip M Pattany; Evelyn M L Sklar; James B Murdoch; Carol K Petito
Journal:  AJNR Am J Neuroradiol       Date:  2003-05       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.